These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 23873719)
1. Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer. Martín M; Custodio S; de Las Casas ML; García-Sáenz JÁ; de la Torre JC; Bellón-Cano JM; López-Tarruella S; Vidaurreta-Lazaro M; de la Orden V; Jerez Y; Márquez-Rodas I; Casado A; Sastre J; Díaz-Rubio E Oncologist; 2013; 18(8):917-23. PubMed ID: 23873719 [TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129 [TBL] [Abstract][Full Text] [Related]
3. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204 [TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. Magbanua MJM; Savenkov O; Asmus EJ; Ballman KV; Scott JH; Park JW; Dickler M; Partridge A; Carey LA; Winer EP; Rugo HS Clin Cancer Res; 2020 Sep; 26(18):4911-4920. PubMed ID: 32586939 [TBL] [Abstract][Full Text] [Related]
5. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259 [TBL] [Abstract][Full Text] [Related]
6. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. Magbanua MJM; Hendrix LH; Hyslop T; Barry WT; Winer EP; Hudis C; Toppmeyer D; Carey LA; Partridge AH; Pierga JY; Fehm T; Vidal-Martínez J; Mavroudis D; Garcia-Saenz JA; Stebbing J; Gazzaniga P; Manso L; Zamarchi R; Antelo ML; Mattos-Arruda L; Generali D; Caldas C; Munzone E; Dirix L; Delson AL; Burstein HJ; Qadir M; Ma C; Scott JH; Bidard FC; Park JW; Rugo HS J Natl Cancer Inst; 2021 Apr; 113(4):443-452. PubMed ID: 32770247 [TBL] [Abstract][Full Text] [Related]
7. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841 [TBL] [Abstract][Full Text] [Related]
8. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer. Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482 [TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial. Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486 [TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Giuliano M; Giordano A; Jackson S; Hess KR; De Giorgi U; Mego M; Handy BC; Ueno NT; Alvarez RH; De Laurentiis M; De Placido S; Valero V; Hortobagyi GN; Reuben JM; Cristofanilli M Breast Cancer Res; 2011 Jun; 13(3):R67. PubMed ID: 21699723 [TBL] [Abstract][Full Text] [Related]
11. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. Wallwiener M; Riethdorf S; Hartkopf AD; Modugno C; Nees J; Madhavan D; Sprick MR; Schott S; Domschke C; Baccelli I; Schönfisch B; Burwinkel B; Marmé F; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A BMC Cancer; 2014 Jul; 14():512. PubMed ID: 25015676 [TBL] [Abstract][Full Text] [Related]
12. Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer. Lee CH; Hsieh JC; Wu TM; Yeh TS; Wang HM; Lin YC; Chen JS; Lee CL; Huang WK; Hung TM; Yen TT; Chan SC; Chou WC; Kuan FC; Hu CC; Chang PH BMC Cancer; 2019 Dec; 19(1):1167. PubMed ID: 31791269 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer. Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662 [TBL] [Abstract][Full Text] [Related]
14. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903 [TBL] [Abstract][Full Text] [Related]
15. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Peeters DJ; van Dam PJ; Van den Eynden GG; Rutten A; Wuyts H; Pouillon L; Peeters M; Pauwels P; Van Laere SJ; van Dam PA; Vermeulen PB; Dirix LY Br J Cancer; 2014 Jan; 110(2):375-83. PubMed ID: 24366294 [TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer. De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193 [TBL] [Abstract][Full Text] [Related]
17. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110 [TBL] [Abstract][Full Text] [Related]
18. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Botteri E; Sandri MT; Bagnardi V; Munzone E; Zorzino L; Rotmensz N; Casadio C; Cassatella MC; Esposito A; Curigliano G; Salvatici M; Verri E; Adamoli L; Goldhirsch A; Nolè F Breast Cancer Res Treat; 2010 Jul; 122(1):211-7. PubMed ID: 19967556 [TBL] [Abstract][Full Text] [Related]
19. Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. Deutsch TM; Riethdorf S; Nees J; Hartkopf AD; Schönfisch B; Domschke C; Sprick MR; Schütz F; Brucker SY; Stefanovic S; Sohn C; Pantel K; Trumpp A; Schneeweiss A; Wallwiener M Breast Cancer Res Treat; 2016 Nov; 160(2):277-290. PubMed ID: 27696083 [TBL] [Abstract][Full Text] [Related]
20. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial. Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W; BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]